Solvonis Therapeutics PLC Proactive Investors interview with Chairman
January 30 2025 - 7:00AM
RNS Non-Regulatory
RNS Number : 3198V
Solvonis Therapeutics PLC
30 January 2025
RNS
Reach - non-regulatory announcement
30 January
2025
Solvonis Therapeutics plc
("Solvonis Therapeutics" or the "Company")
Proactive Investors interview
with Chairman
Solvonis Therapeutics (LON:
SVNS), an innovative biotechnology company
co-developing therapeutics for mental health
disorders, announces that Dennis Purcell, Chairman of the
Company, has recently given an interview to Proactive Investors
about the increasing mergers and acquisitions activity in the
neuroscience sector. The interview can be viewed at
https://www.proactiveinvestors.co.uk/companies/news/1065372/solvonis-therapeutics-chairman-on-the-future-of-biotech-neuroscience-ma.html.
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
Email: anthony@solvonis.com
Allenby Capital (Financial Adviser and Broker)
+44 (0) 20 3328 5656
Nick Naylor
/ Liz Kirchner (Corporate Finance) | Guy McDougall
(Sales)
About Solvonis Therapeutics plc
Solvonis Therapeutics plc is an
innovative biotechnology company focused on developing
intellectual property related to the
treatment of mental health and substance use disorders, and
co-developing therapeutics for mental health disorders. Solvonis'
mission is to improve outcomes for individuals suffering from
mental health disorders, with an initial focus on trauma-related
mental health conditions, such as PTSD. PTSD affected approximately
13 million adults in the U.S. in 2020, with the Company estimating
a current affected population of 20 million across the U.S., UK,
and key EU markets.
www.solvonis.com | LinkedIn
| X (formerly
Twitter)
About Reach announcements
This is an RNS Reach announcement.
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM
Rules for Companies, Market Abuse Regulation or other regulation
would be disseminated as an RNS regulatory announcement and not on
Reach.
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRASDDFFSEISEIF
Solvonis Therapeutics (LSE:SVNS)
Historical Stock Chart
From Jan 2025 to Feb 2025
Solvonis Therapeutics (LSE:SVNS)
Historical Stock Chart
From Feb 2024 to Feb 2025
